progesterone medication naturally occurring steroid progestogen used combination estrogens mainly hormone therapy menopausal symptoms low sex hormone levels also used women support pregnancy fertility treat gynecological progesterone taken mouth vaginally injection muscle fat among progesterone vaginal ring progesterone intrauterine device used birth control also exist areas progesterone well tolerated often produces side however number side effects possible instance mood progesterone taken mouth high doses certain central side effects including sedation sleepiness cognitive impairment also medication naturally occurring progestogen hence agonist progesterone receptor pr biological target progestogens like endogenous opposes effects estrogens various parts body like uterus also blocks effects hormone addition progesterone neurosteroid effects progesterone first isolated pure form first became available medication later oral micronized progesterone omp allowed progesterone taken mouth introduced large number synthetic progestogens progestins derived progesterone used medications examples include medroxyprogesterone acetate commonly prescribed medication united states million progesterone used combination estrogen component menopausal hormone therapy treatment menopausal symptoms peri postmenopausal used specifically provide endometrial protection unopposed estrogeninduced endometrial hyperplasia cancer women intact systematic review endometrial protection progesterone recommended mgday continuous oral progesterone mgday cyclic oral progesterone mgday cyclic vaginal progesterone mg alternateday vaginal twiceweekly mg vaginal progesterone also recommended research needed dose endometrial monitoring may transdermal progesterone recommended endometrial replenish trial first adequately powered study show continuous mgday oral progesterone food provides adequate endometrial cyclic mgday oral progesterone also found effective prevention endometrial hyperplasia instance postmenopausal estrogenprogestin interventions pepi however pepi trial adequately powered fully quantify endometrial hyperplasia cancer adequately powered studies assessed endometrial protection vaginal case early versus late intervention trial estradiol elite found cyclic mgday vaginal progesterone gel showed significant difference placebo endometrial cancer due vaginal firstpass effect low doses vaginal progesterone may allow adequate endometrial although sufficiently powered various smaller studies also found endometrial protection oral vaginal inadequate evidence endometrial protection transdermal progesterone oral progesterone found significantly reduce hot flashes relative combination estrogen oral progesterone likewise reduces hot estrogen plus oral progesterone found significantly improve quality combination estrogen mgday oral progesterone found improve sleep moreover sleep improved significantly better extent estrogen plus medroxyprogesterone may attributable sedative neurosteroid effects reduction hot flashes may also help improve sleep based animal research progesterone may involved sexual function however limited clinical research suggests progesterone improve sexual desire function combination estrogen oral progesterone found improve bone mineral density bmd similar extent estrogen plus medroxyprogesterone progestogens including progesterone may beneficial effects bone independent estrogens although research required confirm combination estrogen oral vaginal progesterone found improve cardiovascular health women early menopause women late estrogen therapy favorable influence blood lipid profile may translate improved cardiovascular addition oral vaginal progesterone neutral beneficial effects contrast various progestins known antagonize beneficial effects estrogens blood progesterone alone combination estrogen found beneficial effects skin slow rate skin aging postmenopausal french observational study risk diabetes significantly lower women menopausal hormone therapy including combination oral transdermal estrogen oral progesterone progesterone used component feminizing hormone therapy transgender women combination estrogens however addition progestogens hrt transgender women controversial role patients clinicians believe anecdotally progesterone may enhance breast development improve mood increase sex however lack evidence welldesigned studies support notions addition progestogens produce undesirable side effects although bioidentical progesterone may safer better tolerated synthetic progestogens like medroxyprogesterone believe progestogens necessary full breast development progesterone sometimes used transgender women intention enhancing breast however review concluded following topic progesterone enhancing breast development transgender knowledge concerning natural history effects different crosssex hormone therapies breast development transgender women extremely sparse based low quality evidence current evidence provide evidence progestogens enhance breast development transgender women neither prove absence effect prevents us drawing firm conclusion moment demonstrates need research clarify important clinical data menstruating women shows correlation water retention levels progesterone despite theorise progesterone might cause temporary breast enlargement due local fluid retention may thus give misleading appearance breast aside hypothetical involvement breast development progestogens otherwise known involved physical vaginally dosed progesterone investigated potentially beneficial preventing preterm birth women risk preterm birth initial study fonseca suggested vaginal progesterone could prevent preterm birth women history preterm according recent study women short cervix received hormonal treatment progesterone gel risk prematurely giving birth reduced hormone treatment administered vaginally every day second half subsequent larger study showed vaginal progesterone better placebo preventing recurrent preterm birth women history previous preterm planned secondary analysis data trial showed women short cervix baseline trial benefit two ways reduction births less weeks reduction frequency time babies intensive another trial vaginal progesterone shown better placebo reducing preterm birth prior weeks women extremely short cervix editorial roberto romero discusses role sonographic cervical length identifying patients may benefit progesterone metaanalysis published found vaginal progesterone cut risk premature births percent women short metaanalysis pooled published results five large clinical trials also found treatment cut rate breathing problems reduced need placing baby progesterone used luteal support assisted reproductive technology art cycles vitro fertilization also used correct luteal phase deficiency prepare endometrium implantation infertility therapy used support early progesterone vaginal ring available birth control breastfeeding number areas intrauterine device containing progesterone also marketed brand name progestasert birth control including previously united progesterone used control persistent anovulatory used nonpregnant women delayed menstruation one weeks order allow thickened endometrial lining slough process termed progesterone withdrawal bleed progesterone taken orally short time usually one week discontinued bleeding occurcitation needed progesterone unclear benefit reversal mifepristoneinduced evidence insufficient support use traumatic brain progesterone used topical medication applied scalp treat female male pattern hair variable effectiveness reported overall effectiveness indication sexes progesterone approved brand name progestogel topical gel local application breasts treat breast pain certain approved systemic found clinical studies inhibit estrogeninduced proliferation breast epithelial cells abolish breast pain tenderness women however one small study women cyclic breast pain vaginal progesterone also found effective treatment breast pain historically progesterone widely used treatment premenstrual cochrane review found insufficient evidence effectiveness progesterone another review studies found progesterone effective condition although stated insufficient evidence available currently make definitive statement progesterone premenstrual progesterone used treat catamenial epilepsy supplementation certain periods menstrual progesterone available variety different forms including oral capsules sublingual tablets vaginal capsules tablets gels suppositories rings rectal suppositories oil solutions intramuscular injection aqueous solutions subcutaneous topical progesterone gel approved local application breasts treat breast pain indicated systemic progesterone previously available intrauterine device use hormonal contraception formulation progesterone also limitedly available combination estrogens estradiol estradiol benzoate use intramuscular addition approved pharmaceutical products progesterone available unregulated custom compounded overthecounter formulations like systemic transdermal creams systemic efficacy transdermal progesterone controversial contraindications progesterone include hypersensitivity progesterone progestogens prevention cardiovascular disease black box warning thrombophlebitis thromboembolic disorder cerebral hemorrhage impaired liver function disease breast cancer reproductive organ cancers undiagnosed vaginal bleeding missed menstruations miscarriage history progesterone used caution people conditions may adversely affected fluid retention epilepsy migraine headaches asthma cardiac dysfunction renal also used caution patients anemia diabetes mellitus history depression previous ectopic pregnancy unresolved abnormal pap use progesterone recommended pregnancy however medication deemed usually safe breastfeeding american academy pediatrics used first four months progesterone formulations contain benzyl alcohol may cause potentially fatal gasping syndrome given premature progesterone well tolerated many clinical studies reported side side effects progesterone may include abdominal cramps back pain breast tenderness constipation nausea dizziness edema vaginal bleeding hypotension fatigue dysphoria depression irritability among central nervous system depression sedation cognitivememory impairment also vaginal progesterone may associated vaginal irritation itchiness discharge decreased libido painful sexual intercourse vaginal bleeding spotting association cramps local warmth feeling coolness without intramuscular injection may cause mildtomoderate pain site high intramuscular doses progesterone associated increased body temperature may alleviated paracetamol progesterone lacks undesirable offtarget hormonal activity contrast various result associated androgenic antiandrogenic estrogenic glucocorticoid conversely progesterone still produce side effects related antimineralocorticoid neurosteroid compared progestin medroxyprogesterone acetate fewer reports breast tenderness addition magnitude duration vaginal bleeding progesterone reported lower medroxyprogesterone progesterone produce central nervous system depression adverse effect particularly oral administration high doses side effects may include drowsiness sedation sleepiness fatigue sluggishness reduced vigor dizziness lightheadedness confusion cognitive memory andor motor limited available evidence shown minimal adverse influence cognition oral progesterone mg vaginal progesterone mg gel progesterone intramuscular injection however high doses oral progesterone mg vaginal progesterone mg intramuscular progesterone mg found result dosedependent fatigue drowsiness decreased moreover high single doses oral progesterone mg produced significant cognitive memory intravenous infusion high doses progesterone eg mg found induce deep sleep individuals sensitive experience considerable sedative hypnotic effects lower doses oral progesterone eg sedation cognitive memory impairment progesterone attributable inhibitory neurosteroid metabolites occur greater extent oral progesterone may minimized switching parenteral progesterone also taken bed avoid side effects help neurosteroid effects progesterone unique progesterone shared breast cell proliferation found significantly increased combination oral estrogen plus cyclic medroxyprogesterone acetate postmenopausal women combination transdermal estradiol plus oral studies topical estradiol progesterone applied breasts weeks found result highly pharmacological local levels estradiol studies assessed breast proliferation markers found increased proliferation estradiol alone decreased proliferation progesterone change proliferation estradiol progesterone postmenopausal estrogenprogestin interventions pepi trial combination estrogen cyclic oral progesterone resulted higher mammographic breast density estrogen alone vs nonsignificantly lower breast density combination estrogen cyclic continuous medroxyprogesterone acetate vs higher breast density strong known risk factor breast studies mixed findings systematic review reported breast density estrogen plus oral progesterone significantly increased three studies unchanged two changes breast density progesterone appear less compared large shortterm observational studies estrogen alone combination estrogen oral progesterone generally associated increased risk breast conversely combination estrogen almost progestin medroxyprogesterone acetate norethisterone acetate associated increased risk breast exception among progestins dydrogesterone shown similar risk oral breast cancer risk estrogen progestin therapy durationdependent risk significantly greater years exposure relative less contrast shorterterm studies longerterm observations years french study showed significant associations estrogen plus oral progesterone estrogen plus dydrogesterone higher breast cancer risk similarly estrogen plus oral progesterone low bioavailability relatively weak progestogenic delayed onset breast cancer risk estrogen plus oral progesterone potentially consistent weak proliferative effect oral progesterone longer duration exposure may necessary detectable increase breast cancer risk case risk remains lower systematic review progesterone breast cancer concluded shortterm use years associated greater conclusions progesterone metaanalysis worldwide epidemiological evidence collaborative group hormonal factors breast cancer data breast density changes breast cancer risk oral data breast safety vaginal progesterone early versus late intervention trial estradiol elite randomized controlled trial postmenopausal women used estradiol mgday cyclic vaginal incidence breast cancer reported adverse absolute incidences cases estradiol plus vaginal progesterone group cases control however study adequately powered quantifying breast cancer whereas combination estrogen progestin associated increased risk venous thromboembolism vte relative estrogen alone difference risk vte combination estrogen oral progesterone relative estrogen hence contrast progestins oral progesterone added estrogen appear increase coagulation vte reason differences progesterone progestins terms vte risk however may due low progesterone levels relatively weak progestogenic effects produced oral contrast oral progesterone nonoral achieve much higher progesterone assessed terms vte progesterone likely relatively safe overdose levels progesterone pregnancy higher normal menstrual cycling although levels increase gradually course oral dosages progesterone high mgday assessed clinical trials main side effect case report progesterone misuse oral dosage mg per administration much mg progesterone intravenous infusion humans uneventful terms toxicity induce deep sleep though individuals still able awakened sufficient several notable drug interactions progesterone certain selective serotonin reuptake inhibitors ssris fluoxetine paroxetine sertraline may increase gabaa receptorrelated central depressant effects progesterone enhancing conversion allopregnanolone via activation progesterone potentiates sedative effects benzodiazepines notably case report progesterone abuse alone high inhibitors finasteride dutasteride inhibit conversion progesterone inhibitory neurosteroid allopregnanolone reason may potential reduce sedative related effects progesterone weak significant agonist pregnane x receptor pxr found induce several hepatic cytochrome enzymes especially concentrations high pregnancy range progesterone may potential accelerate metabolism various progesterone progestogen agonist nuclear progesterone receptors prs pra prb addition progesterone agonist membrane progesterone receptors mprs including mprα mprβ mprγ mprδ aside prs mprs progesterone potent antimineralocorticoid antagonist mineralocorticoid receptor biological target mineralocorticoid addition activity steroid hormone progesterone among neurosteroid activities via active metabolites allopregnanolone pregnanolone progesterone potent positive allosteric modulator gabaa receptor major signaling receptor inhibitory neurotransmitter γaminobutyric acid prs expressed widely throughout body including uterus cervix vagina fallopian tubes breasts fat skin pituitary gland hypothalamus areas accordance progesterone numerous effects throughout among effects progesterone produces changes female reproductive system breasts progesterone functional antiestrogenic effects due progestogenic activity including uterus cervix effects progesterone may influence health positive negative addition aforementioned effects progesterone antigonadotropic effects due progestogenic activity inhibit ovulation suppress gonadal sex hormone activities progesterone besides mediated prs mprs also progesterone lowers blood pressure reduces water salt retention among effects via antimineralocorticoid addition progesterone produce sedative hypnotic anxiolytic euphoric cognitive memory motorimpairing anticonvulsant even anesthetic effects via formation sufficiently high concentrations neurosteroid metabolites consequent gabaa receptor potentiation differences progesterone progestins medroxyprogesterone acetate norethisterone implications pharmacodynamics pharmacokinetics well efficacy tolerability pharmacokinetics progesterone dependent route administration medications approved form oilfilled capsules containing micronized progesterone oral administration termed oral micronized progesterone also available form vaginal rectal suppositories pessaries topical creams oil solutions intramuscular injection aqueous solutions subcutaneous routes administration progesterone used include oral intranasal transdermaltopical vaginal rectal intramuscular subcutaneous intravenous vaginal progesterone available form progesterone capsules tablets inserts gels suppositories pessaries bioavailability progesterone commonly overestimated due immunoassay method analysis failing distinguish progesterone newer methods adjusted oral bioavailbility estimate less progesterone naturally occurring pregnane steroid also known double bond positions two ketone groups one position due pregnane core double bond progesterone often abbreviated contrasted pregnenolone double bond often abbreviated large number progestins synthetic progestogens derived categorized several structural groups including derivatives retroprogesterone respective example group including dydrogesterone medroxyprogesterone acetate medrogestone progesterone ethers quingestrone progesterone enol ether progesterone enol ether among examples belong another major group progestins derivatives exemplified norethisterone norethindrone levonorgestrel derived progesterone rather variety synthetic inhibitory neurosteroids derived progesterone neurosteroid metabolites allopregnanolone examples include alfadolone alfaxolone ganaxolone hydroxydione minaxolone addition conjugates progesterone progesterone carboxymethyloxime progesterone progesterone progesterone sodium salt progesterone chemical structure unreleased developed watersoluble prodrugs progesterone neurosteroid chemical syntheses progesterone hormonal action progesterone discovered pure crystalline progesterone isolated chemical structure later year chemical synthesis progesterone shortly following chemical synthesis progesterone began tested clinically schering introduced progesterone oil solution medication intramuscular injection brand name first pharmaceutical formulation progesterone marketed medical initially corpus luteum extract becoming pure synthesized progesterone clinical study formulation published multiple formulations progesterone oil solution intramuscular injection brand names proluton progestin gestone available parenteral route used oral progesterone low activity thought progesterone initially expensive due large doses however start steroid manufacturing diosgenin costs greatly subcutaneous pellet implants progesterone first studied women late first longacting progestogen pellets reported extruded skin within weeks high rates even implanted beneath deep fascia also produced frequent inflammatory reactions site addition absorbed slowly achieved unsatisfactorily low progesterone consequently soon abandoned favor preparations aqueous however subcutaneous pellet implants progesterone later studied form birth control women early though preparations ultimately aqueous suspensions progesterone crystals intramuscular injection first described preparations market variety brand names including flavolutan luteosan lutocyclin lutren among aqueous suspensions steroids developed showed much longer durations intramuscular injection steroids oil however local injection site reactions occur oil solutions limited clinical use aqueous suspensions progesterone today preparation brand name agolutin depot remains market czech republic combined preparation progesterone estradiol benzoate lidocaine remains available brand name clinomin forte paraguay addition aqueous suspensions waterinoil emulsions steroids studied longacting emulsions progesterone introduced use intramuscular injection brand names progestin diproemulsion estradiol benzoate due lack standardization crystal sizes crystalline suspensions steroids marked variations emulsions said even macrocrystalline aqueous suspensions progesterone well microspheres progesterone investigated potential progestogenonly injectable contraceptives combined injectable contraceptives estradiol late early never aqueous solutions waterinsoluble steroids first developed via association colloid solubility enhancers aqueous solution progesterone use intravenous injection marketed schering ag brand name primolut intravenous one intended uses treatment threatened abortion rapidacting effect aqueous solution progesterone complexed cyclodextrin increase water solubility introduced use oncedaily subcutaneous injection europe brand name prolutex longacting parenteral progestins hydroxyprogesterone caproate medroxyprogesterone acetate norethisterone enanthate developed introduced use intramuscular lacked need frequent injections injection site reactions associated progesterone intramuscular injection soon supplanted progesterone parenteral therapy first study oral progesterone humans published found oral progesterone produced significant progestational effects endometrium prior study animal research suggested oral progesterone inactive reason oral progesterone never evaluated variety early studies oral progesterone humans also published studies generally reported oral progesterone weakly oral nonmicronized progesterone introduced pharmaceutical medication around instance cyclogesterin mg estrogenic substances mg progesterone tablets menstrual disturbances upjohn though saw limited another preparation contained progesterone alone synderone trademark registered chemical specialties sublingual progesterone women first studied robert buccal progesterone tablets marketed schering brand name proluton buccal tablets sublingual progesterone tablets marketed brand names progesterone lingusorbs progesterone membrettes sublingual tablet formulation progesterone approved brand name luteina poland ukraine remains marketed progesterone first progestogen found inhibit ovulation animals injections progesterone first shown inhibit ovulation animals inhibition fertilization administration progesterone luteal phase also demonstrated animals ovulation inhibition progesterone animals subsequently reconfirmed expanded gregory pincus colleagues findings inhibition ovulation progesterone women first presented fifth international conference planned parenthood tokyo japan october three different research groups presented findings topic included pincus conjunction john rock attend conference ninemember japanese group led masaomi ishikawa twomember team abraham stone herbert conference marked beginning new era history birth results subsequently published scientific journals case pincus case ishikawa rock pincus also subsequently described findings pseudopregnancy therapy combination high doses diethylstilbestrol oral progesterone prevented ovulation pregnancy unfortunately use oral progesterone hormonal contraceptive plagued included large extension expensive doses required incomplete inhibition ovulation even high doses frequent incidence breakthrough tokyo conference pincus also presented first findings ovulation inhibition oral progestins animals specifically derivatives like noretynodrel progestins far potent progesterone requiring much smaller doses december inhibition ovulation oral noretynodrel norethisterone demonstrated findings well results animals published noretynodrel norethisterone show problems associated oral studies fully inhibited ovulation produce menstruationrelated side consequently oral progesterone abandoned hormonal contraceptive first birth control pills introduced noretynodrelcontaining product norethisteronecontaining product followed numerous others containing diversity progesterone never introduced use birth control modern clinical studies oral progesterone demonstrating elevated levels progesterone endorgan responses women specifically progestational endometrial changes published point many clinicians researchers apparently still thought oral progesterone almost half century introduction progesterone medicine reasonably effective oral formulation progesterone micronization progesterone suspension oilfilled capsules allowed progesterone absorbed severalfold efficiently oral route first studied late described literature formulation known oral micronized progesterone omp introduced medical use brand name utrogestan france subsequently oral micronized progesterone introduced brand name prometrium united states oral micronized progesterone marketed first combination oral estradiol progesterone introduced brand name bijuva united sustainedrelease sr formulation oral micronized progesterone also known oral natural micronized progesterone sustained release oral nmp sr marketed india brand name gestofit many additional brand names preparation originally developed compounding pharmacy called madison pharmacy associates madison wisconsin united vaginal progesterone suppositories first studied women robert greenblatt shortly thereafter vaginal progesterone suppositories introduced medical use brand name colprosterone rectal progesterone suppositories first studied men women christian hamburger vaginal rectal progesterone suppositories introduced use brand name cyclogest vaginal micronized progesterone gels capsules introduced medical use brand names utrogestan crinone early progesterone approved united states vaginal gel vaginal insert progesterone contraceptive vaginal ring known progering first studied women continued researched approved use contraceptive lactating mothers latin america second progesterone vaginal ring known fertiring developed progesterone supplement use assisted reproduction approved latin america development progesteronecontaining intrauterine device iud contraception began incorporation progesterone iuds initially studied help reduce risk iud however addition progesterone iuds showed benefit expulsion rates unexpectedly found induce endometrial led development introduction progestasert progesteronecontaining product first progestogencontaining unfortunately product various problems limited included short duration efficacy one year high cost relatively high failure rate lack protection ectopic pregnancy difficult sometimes painful insertions could necessitate use local anesthetic result issues progestasert never became widely used discontinued used mostly united states france topical gel formulation progesterone direct application breasts local therapy breast disorders breast pain introduced brand name progestogel europe transdermal formulations progesterone systemic use successfully marketed spite efforts pharmaceutical companies towards low potency transdermal progesterone thus far precluded although formulations transdermal progesterone approved systemic use transdermal progesterone available form creams gels custom compounding pharmacies countries also available overthecounter without prescription united however preparations unregulated adequately characterized low unsubstantiated progesterone generic name drug english inntooltip inn usantooltip united states adopted name usptooltip united states pharmacopeia bantooltip british approved name dcittooltip denominazione comune italiana jantooltip japanese accepted name progestérone name french dcftooltip dénomination commune also referred progesteronum latin progesterona spanish portuguese progesteron progesterone marketed large number brand names throughout examples major brand names progesterone marketed include crinone crinone cyclogest endogest endometrin estima geslutin gesterol gestone luteina luteinol lutigest lutinus microgest progeffik progelan progendo progering progest progestaject progestan progesterone progestin progestogel prolutex proluton prometrium prontogest strone susten utrogest progesterone widely available countries throughout world variety progesterone form oral capsules vaginal capsules tabletsinserts gels intramuscular oil widespread following formulationsroutes progesterone selective limited addition singledrug formulations following progesterone combination formulations marketed albeit limited november progesterone available united states following mgml concentration progesterone oil intramuscular injection mgdevice progesterone intrauterine device progestasert oral combination formulation micronized progesterone estradiol oilfilled capsules brand name bijuva marketed united states treatment menopausal symptoms endometrial progesterone also available unregulated custom preparations compounding pharmacies united addition transdermal progesterone available overthecounter united states although clinical efficacy transdermal progesterone progesterone studied progestogenonly injectable contraceptive never combinations estradiol progesterone macrocrystalline aqueous suspension aqueous suspension microspheres studied onceamonth combined injectable contraceptives likewise never progesterone assessed suppression sex drive spermatogenesis one study mg rectal suppositories progesterone given five times per day days resulted progesterone levels ngml suppressed circulating testosterone growth hormone levels men affect libido erectile potency short treatment studies mgday progesterone intramuscular injection weeks men produced azoospermia decreased testicular size markedly suppressed libido erectile potency resulted minimal semen volume upon oil water nanoemulsion progesterone particles mm diameter using micellar nanoparticle technology transdermal administration known progestsorb ne development novavax use menopausal hormone therapy however development discontinued formulation never